Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib ...

New York, USA, Feb. 28, 2025 (GLOBE NEWSWIRE) -- OPZELURA Continues to Revolutionize the Dermatology Market with Strong Market Uptake | DelveInsight OPZELURA (ruxolitinib cream) has shown strong ...

Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Citi keeps a Buy rating on Incyte (INCY) with an $88 price target after the company presented data from its pivotal Phase 3 TRuE-PN1 trial ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first FDA ...

OPZELURA Continues to Revolutionize the Dermatology Market with Strong Market Uptake | DelveInsight OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in ...